HOME > PRACTICE MANAGEMENT > CLINICAL SUPPORT > QUALITY Drug Safety - Table 1

Drug Safety - Table 1

Return to Quality Home


Table 1.  Baseline laboratory monitoring for disease modifying anti-rheumatic drugs.

Drug

Hemoglobin or Hematocrit

WBC

Platelet Count

Serum Creatinine

AST
or
ALT

Albumin

Alkaline
Phosphatase

CXR†

Chemistry
Panel

Other

Hydroxychloroquine‡

 

 

 

 

 

 

 

 

 

 

Sulfasalazine

X

X

X

 

X

X

 

 

 

Urinary protein

Methotrexate

X

X

X

X

X

X

X

X

 

 

Leflunomide

X

X

X

X

X

X

 

 

 

 

Etanercept

 

 

 

 

 

 

 

X

 

PPD

Kineret

 

 

 

 

 

 

 

X

 

PPD

Infliximab

 

 

 

 

 

 

 

X

 

PPD

Adalimumab

 

 

 

 

 

 

 

X

 

PPD

Azathioprine

X

X

X

X

X

X

 

 

 

 

Intramuscular Gold

X

X

X

X

 

 

 

 

 

Urinary protein

Oral Gold

X

X

X

 

 

 

 

 

 

urinalysis

Cyclosporine

X

X

X

X

X

X

 

 

 

Uric acid and blood pressure

Oral glucocorticoids

 

 

 

 

 

 

 

 

X

Blood pressure
DEXA scan§

*WBC = white blood cell count; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CXR = chest radiograph; PPD = purified protein derivative standard; DEXA = dual-energy x-ray absorptiometry; † within previous year; ‡ no baseline monitoring; § within 6 months of initiating continuous therapy at an average dose of 7.5 mg/day.

Back to Drug Safety QPI